Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Lymphoma, Non-Hodgkin 3Lymphoma, B-Cell 2Lymphoma 2Triple Negative Breast Neoplasms 1Neuroblastoma 1Multiple Myeloma 1Lymphoma, T-Cell 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, Large B-Cell, Diffuse 1Leukemia, Prolymphocytic, B-Cell 1Leukemia, Myeloid, Acute 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia, B-Cell 1Leukemia 1Hodgkin Disease 1Hematologic Diseases 1Ganglioneuroblastoma 1Burkitt Lymphoma 1

Interventions

fludarabine 3Cyclophosphamide 3obinutuzumab 2acalabrutinib 2ricolinostat 1pirtobrutinib 1idelalisib 1ibrutinib 1fludarabine phosphate 1Rituximab 1Mesna 1Leukapheresis 1ARQ531 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Leukemia, B-Cell × Leukapheresis × 30 days × Clear all
NCT01087294 2026-06-01

Administration of Anti-CD19-chimeric-antigen-receptor-transduced T Cells From the Original Transplant Donor to Patients With Recurrent or Persistent B-cell Malignancies After Allogeneic Stem Cell Transplantation

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
85 enrolled
LymphoidOther hematologic neoplasm

Hodgkin Disease, Lymphoma, Non-Hodgkin, Leukemia, B-Cell, Lymphoma, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡